Exact Sciences's gross profit for the
three
months ended in Sep. 2024 was $513 Mil. Exact Sciences's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $1,965 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Exact Sciences's gross profit for the
three
months ended in Sep. 2024 was $513 Mil. Exact Sciences's Revenue for the
three
months ended in Sep. 2024 was $709 Mil. Therefore, Exact Sciences's Gross Margin % for the quarter that ended in Sep. 2024 was 72.33%.
Exact Sciences had a gross margin of 72.33% for the quarter that ended in Sep. 2024 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Exact Sciences was 76.24%. The lowest was -139.15%. And the median was 73.14%.
Exact Sciences Gross Profit Historical Data
The historical data trend for Exact Sciences's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Exact Sciences's Gross Profit
For the Diagnostics & Research subindustry, Exact Sciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exact Sciences's Gross Profit Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Gross Profit distribution charts can be found below:
* The bar in red indicates where Exact Sciences's Gross Profit falls into.
Exact Sciences Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Exact Sciences's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,965 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Exact Sciences had a gross margin of 72.33% for the quarter that ended in Sep. 2024 => Durable competitive advantage
Exact Sciences Gross Profit Related Terms
Thank you for viewing the detailed overview of Exact Sciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EXAS has been successfully added to your 